These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29371923)

  • 1. Targeting the
    Caporali S; Alvino E; Lacal PM; Ruffini F; Levati L; Bonmassar L; Scoppola A; Marchetti P; Mastroeni S; Antonini Cappellini GC; D'Atri S
    Oncotarget; 2017 Dec; 8(69):113472-113493. PubMed ID: 29371923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
    Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
    Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
    J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
    Caporali S; Alvino E; Levati L; Esposito AI; Ciomei M; Brasca MG; Del Bufalo D; Desideri M; Bonmassar E; Pfeffer U; D'Atri S
    Biochem Pharmacol; 2012 Sep; 84(5):598-611. PubMed ID: 22704958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.
    Acciardo S; Mignion L; Joudiou N; Bouzin C; Baurain JF; Gallez B; Jordan BF
    Oncotarget; 2018 Mar; 9(24):16832-16846. PubMed ID: 29682188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion.
    Zheng Y; Guo J; Zhou J; Lu J; Chen Q; Zhang C; Qing C; Koeffler HP; Tong Y
    BMC Med Genomics; 2015 Aug; 8():49. PubMed ID: 26264222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of Pituitary Tumor Transforming Gene-1 Regulates Trophoblast Invasion via the Integrin/Rho-Family Signaling Pathway.
    Lim SM; Jang HY; Lee JE; Shin JS; Park SH; Yoon BH; Kim GJ
    PLoS One; 2016; 11(2):e0149371. PubMed ID: 26900962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.
    Rutkowski P; Blank C
    Expert Opin Drug Saf; 2014 Sep; 13(9):1249-58. PubMed ID: 25014231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
    Gibney GT; Zager JS
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Doses of Celecoxib Might Promote Phenotype Switching in Cutaneous Melanoma Treated with Dabrafenib-Preliminary Study.
    Tudor DV; Florea A; Cenariu M; Olteanu DE; Farcaș M; Hopârtean A; Clichici SV; Filip GA
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of pituitary tumor transforming gene 1 in psoriasis, seborrheic keratosis, and skin tumors.
    Cai SQ; Dou TT; Li W; Li SQ; Chen JQ; Zhou J; Zheng M; Man XY
    Discov Med; 2014 Dec; 18(101):289-99. PubMed ID: 25549700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop.
    Liang HQ; Wang RJ; Diao CF; Li JW; Su JL; Zhang S
    Oncotarget; 2015 Oct; 6(30):29413-27. PubMed ID: 26320179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
    Matter-Walstra K; Braun R; Kolb C; Ademi Z; Dummer R; Pestalozzi BC; Schwenkglenks M
    Br J Dermatol; 2015 Dec; 173(6):1462-70. PubMed ID: 26332527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
    J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.